COMPANY

Allarity Therapeutics

HQ: Boston, MA source · allarity.com ↗ · New England

Keywords: small molecule oncology ovarian cancer Metastatic Breast Cancer Advanced Ovarian Cancer Relapsed/Refractory Multiple Myeloma PARP inhibitor 2X-121 LiPlaCis APO010

Location: Boston, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

8Trials (company is sponsor)

Timeline

Jul 15, 2025 Partnership Partnership / licensing announced Jul 15, 2025. Source: SEC filing. source ↗
Jun 4, 2025 Partnership Partnership / licensing announced Jun 4, 2025. Source: SEC filing. source ↗
Mar 8, 2023 Trial start Phase 1: Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors source ↗
Mar 1, 2021 Trial start Phase 2: Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. source ↗
Apr 15, 2019 Trial start Phase 2: Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer source ↗
Apr 11, 2019 Trial start —: Clinical Pre-screening Protocol for Ovarian Cancer source ↗
Oct 17, 2018 Trial start Phase 2: Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) source ↗
Jun 20, 2018 Trial start Phase 2: Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP source ↗
Jun 13, 2017 Trial start Phase 1/Phase 2: Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP source ↗
2013-04 Trial start I: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours source ↗

Upcoming milestones

2027-03 (ESTIMATED) · Phase 2 · Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer · NCT03878849
2027-06 (ESTIMATED) · · Clinical Pre-screening Protocol for Ovarian Cancer · NCT03877796

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Jul 15, 2025 Partnership / licensing announced Jul 15, 2025. Source: SEC filing. source ↗
Jun 4, 2025 Partnership / licensing announced Jun 4, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT03877796	Clinical Pre-screening Protocol for Ovarian Cancer	Not listed	Recruiting	Apr 11, 2019	2027-06 (estimated)
NCT05571969	Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors	Phase 1	Terminated	Mar 8, 2023	Feb 19, 2024 (actual)
NCT04796324	Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.	Phase 2	Terminated	Mar 1, 2021	Dec 1, 2024 (actual)
NCT03878849	Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer	Phase 2	Recruiting	Apr 15, 2019	2027-03 (estimated)
NCT03562832	Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP	Phase 2	Completed	Jun 20, 2018	Apr 1, 2024 (actual)
NCT03643107	Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)	Phase 2	Completed	Oct 17, 2018	Oct 1, 2021 (actual)
NCT01861496	Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours	I	Completed	2013-04	2021-10 (actual)
NCT03196947	Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP	Phase 1/Phase 2	Terminated	Jun 13, 2017	Jan 16, 2020 (actual)